Amjin's layoff sales team expands its business layout in the Chinese market

Pharmaceutical network February 8th, Anjin cut sales team, what is the signal? Anjin plans to cut 500 jobs, mainly for its sales team, according to foreign media Fierce Pharma.
Reportedly, the California-based drugmaker confirmed Wednesday that it will cut jobs in the future, mainly in the U.S., as amser plans to shift its focus to upcoming drug and product lines and adopt digital marketing tools for the new crown outbreak.
spokesman confirmed that about 500 people were involved in the job cuts.
"We are changing to better leverage the additional investments we believe are needed to take advantage of patient-centric opportunities, including the introduction of new products and investment in research and development," the company said in an emailed statement.
decisions will not be easy and we are committed to helping those affected with transitional support.
report, Amjin would not disclose details of which product teams or therapeutic areas would be affected by the cuts. murdo Gordon,
's executive vice president of global business operations, acknowledged the restructuring without providing details and said the company was focused on a "holistic business model" to "improve productivity and efficiency". peter Griffith,
's chief financial officer, did point out that digital work would lead to lower sales costs and lower general and administrative costs, "which will increase the focus on digital work as a result of changes in our business model".
gordon points out that AMSM expands its traditional marketing efforts through efficient digital communication channels.
that Amjin's cuts to its U.S. operations were accompanied by "massive investments" in Japan, China and Russia.
, like many other pharmaceutical companies, Amjin's use of digital channels is the result of a pandemic that has accelerated the shift to technology channels.
"COVID-19 is leading to some lasting changes in the way we do business.
, for example, we want to continue to use digital capabilities to reach customers and conduct clinical trials around the world faster, with greater efficiency and efficiency.
" chief executive, Robert Bradway, said by phone.
expanding its business in China by 2020, Amjin's sales rose 9 percent to $25.4 billion, exceeding analysts' expectations, although sales fell as the impact of the COVID-19 pandemic offset sales growth.
the layoffs, Amgen will shift from neuroscience to oncology, cardiovascular disease and inflammatory diseases, and although Amgen is laying off U.S. groups, it has also announced that it will expand its business in the Chinese market.
, for example, the industry has reported that Amjin China will begin laying off workers in December 2020 who are not on the national health-care negotiating product line.
this, Amjin China has officially responded: the relevant information is not true, Anjin China's product line team is in normal operation.
, Amjin is indeed gradually expanding its sales in China.
on November 1, 2019, he signed a global strategic partnership with Baiji Shenzhou.
Baiji Shenzhou will buy about $2.7 billion worth of Baiji Shenzhou common stock and gain a seat on the board of directors of Baiji Shenzhou for a total price of not more than $1.25 billion for the China regional interest in three listed products and 20 China regional interests in the tumor development pipeline.
But there is a view in the industry that Amjin's sales capabilities in China still need to be improved - seven years into China, until 2018 to approve Repatha, Amjin in a short period of time to build Repatha's sales team, there is no energy to build other teams.
China is a diversified market that must fully understand itself, its patients, and its competitors, and take a step forward in pricing.
analysts in the snowball pointed out: for example, access to health care, price negotiations is also a technical brain burn, how to understand the direction of policy also let foreigners crazy.
Therefore, in order to spread quickly in the Chinese market, we must find professional managers like Wu Xiaobin, who understand both the original overseas innovative drugs and the Chinese market, which is one of the reasons why Anjin and Baiji Shenzhou cooperate.
Digital marketing or future trends need to be noted that, as the world's leading multinational pharmaceutical companies, Amjin's transition to digital work, with the impact of the new crown outbreak, but also to reduce the cost of sales considerations, which may bring inspiration and demonstration to other pharmaceutical companies.
outbreak has also had an impact on academic conferences and in-house marketing of domestic pharmaceutical companies.
February 2020, the Chinese Medical Association informed the specialized branch that it would postpone all academic meetings from February to April, and that academic meetings in May and beyond would be further studied as the outbreak developed.
Has been told by industry insiders that over the years, the field of expertise still depends on large-scale academic conferences to influence top experts, top experts to cover second-tier city medical experts, and then through different dimensions of the meeting down, to complete the change in doctors' perceptions.
Because the outbreak is not over, meetings cannot be conducted normally, doctors' communication and education are difficult to complete, and medical representatives have difficulty restoring comprehensive doctor communication activities, such as regular visits to hospitals, meetings with doctors, and organization of meetings.
, the outbreak has provided most pharmaceutical companies with opportunities and solutions for digital empowerment, such as accelerating the development of Internet plus healthcare.
new crown outbreak not only restricts normal academic promotion activities, but also makes the cost pressure on foreign enterprises more.
Seber Blue learned that foreign companies for the budget control is very strict, once their budget and the planned income and expenditure is not matched, will make an adjustment, and the new crown outbreak on most pharmaceutical companies have a negative impact on revenue.
In this way, the state of fee control, shrinking resources will become the vast majority of foreign enterprises, the next few years of the regular state, we will cut funds, strengthen process management, improve the requirements of details, to have a clearer goal, improve the capital profit margin;
this time explicitly proposed a shift to digital work, or a start.